For decades, surgery for brain hemorrhage carried a quiet stigma. Two landmark trials had already tried to prove it works and came up empty. In 2024, a new trial finally cracked the code, but only for a specific type of patient. Here is what changed, and why it matters.

🩸 THE PROBLEM

Spontaneous intracerebral hemorrhage, a stroke caused by bleeding directly into the brain rather than a clot blocking a vessel, kills roughly 40 percent of patients within a month. Only 10 to 25 percent ever regain functional independence. Removing the clot surgically seems obvious. Getting the evidence to support it has been anything but.

📉 WHY SURGEONS HAD GIVEN UP HOPE

Two major trials tried and failed to prove surgery helps.

STICH I, published in 2005, randomized patients with spontaneous ICH to early surgical evacuation versus initial medical management. Result: no significant difference in outcomes. Surgery did not clearly help.

STICH II, published in 2013, narrowed the focus to patients with more favorable, superficial lobar hemorrhages, betting that a more selective population would reveal a benefit. It still came up short on its primary outcome.

Together, these trials cemented over a decade of caution. The 2022 AHA and ASA guidelines reflected that uncertainty, and blood pressure control rather than surgery became the dominant lever for improving ICH outcomes, guided by trials like INTERACT2 and ATACH-2, which tested how aggressively to lower blood pressure after a bleed. INTERACT2 suggested intensive blood pressure lowering was safe and possibly beneficial. ATACH-2 later found that pushing blood pressure even lower than standard targets added risk without added benefit. Between them, these trials shaped the medical management arm that every surgical trial since has had to compete against.

⚡ ENTER ENRICH

Published in the New England Journal of Medicine in 2024, ENRICH is the trial that finally moved the needle. It tested a newer, less invasive surgical technique called minimally invasive trans-sulcal parafascicular surgery, MIPS for short, which uses a tubular retractor to reach and remove the clot while minimizing damage to surrounding brain tissue, a meaningfully gentler approach than the open craniotomies used in earlier trials.

300 patients across 37 US centers Hemorrhage volume 30 to 80 mL Surgery within 24 hours of onset Primary outcome: a quality of life weighted disability score at 180 days

📊 THE NUMBERS

Surgery group score: 0.458 Medical management group score: 0.374 Difference: 0.084, with 98.1 percent Bayesian probability that surgery was better

The benefit was not evenly spread. In lobar hemorrhages, the more superficial bleeds, the difference jumped to 0.127. In deep basal ganglia hemorrhages, there was no benefit at all, and enrollment for that subgroup was stopped early because it clearly was not working.

Thirty day mortality told a similarly stark story. 9.3 percent died in the surgery group versus 18.0 percent in the medical management group, a difference researchers were 98.7 percent confident was real. Rebleeding after surgery, the complication everyone worries about, occurred in just 3.3 percent of surgical patients.

🔬 WHY THIS ACTUALLY MAKES BIOLOGICAL SENSE

The logic is straightforward once you see it. A blood clot sitting in brain tissue is not inert. It swells the surrounding area, raises pressure inside the skull, and releases breakdown products that are toxic to nearby neurons. The longer it sits, the more damage accumulates. Removing it early, through a corridor that avoids tearing through critical white matter tracts, interrupts that injury cascade before it becomes irreversible.

🏥 WHAT THIS MEANS IN PRACTICE

ENRICH does not say surgery works for everyone with a brain bleed. It says surgery works for a specific, well defined group, lobar location, right size window, right technique, right speed. For hospital teams, especially anesthesia and critical care staff, that translates into a much tighter operational demand: fast coagulopathy reversal, disciplined blood pressure control going into the OR, and readiness to move within hours rather than days.

The open questions are exactly what you would expect. Does this benefit hold up in younger patients, in patients with bleeding disorders, or in deep hemorrhages using a different technique. Those answers are still pending, and they are precisely where the next round of trials is headed.